Abstract
Human immunodeficiency virus (HIV) is the responsible causal agent of acquired immunodeficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, allowing the entry of opportunistic infections. HIV infection in humans is considered pandemic by the World Health Organization (WHO). HIV needs to use a protein as a co-receptor to enter its target cells. Several chemokine receptors can in principle act as viral co-receptors, but the chemokine (C-C motif) receptor 5 (CCR5) is likely the most physiologically important co-receptor during natural infection. For this reason the development of new CCR5 inhibitors like anti-HIV agents, constitutes a challenge for the scientific community. The present review will focus on the current state of the design of novel anti-HIV drugs, and how the existing computer aided-drug design methodologies, have been effective in the search of new anti-HIV agents. In addition, a QSAR model based on substructural descirptors is presented as a rapid, rational and promising alternative for the discovery of anti-HIV agents through the inhibition of the CCR5.
Keywords: CCR5 inhibitors, QSAR, 3D-QSAR, anti-HIV, linear discriminant analysis, fragments, X-ray crystallography, NMR spectroscopy, molecular descriptors, drug design
Current Computer-Aided Drug Design
Title: Current Drug Design of Anti-HIV Agents Through the Inhibition of C-C Chemokine Receptor Type 5
Volume: 7 Issue: 4
Author(s): Alejandro Speck-Planche and Maria Natalia Dias Soeiro Cordeiro
Affiliation:
Keywords: CCR5 inhibitors, QSAR, 3D-QSAR, anti-HIV, linear discriminant analysis, fragments, X-ray crystallography, NMR spectroscopy, molecular descriptors, drug design
Abstract: Human immunodeficiency virus (HIV) is the responsible causal agent of acquired immunodeficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, allowing the entry of opportunistic infections. HIV infection in humans is considered pandemic by the World Health Organization (WHO). HIV needs to use a protein as a co-receptor to enter its target cells. Several chemokine receptors can in principle act as viral co-receptors, but the chemokine (C-C motif) receptor 5 (CCR5) is likely the most physiologically important co-receptor during natural infection. For this reason the development of new CCR5 inhibitors like anti-HIV agents, constitutes a challenge for the scientific community. The present review will focus on the current state of the design of novel anti-HIV drugs, and how the existing computer aided-drug design methodologies, have been effective in the search of new anti-HIV agents. In addition, a QSAR model based on substructural descirptors is presented as a rapid, rational and promising alternative for the discovery of anti-HIV agents through the inhibition of the CCR5.
Export Options
About this article
Cite this article as:
Speck-Planche Alejandro and Natalia Dias Soeiro Cordeiro Maria, Current Drug Design of Anti-HIV Agents Through the Inhibition of C-C Chemokine Receptor Type 5, Current Computer-Aided Drug Design 2011; 7 (4) . https://dx.doi.org/10.2174/157340911798260287
DOI https://dx.doi.org/10.2174/157340911798260287 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?
Current Pharmaceutical Design Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Current Cancer Therapy Reviews Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives
Current Cancer Therapy Reviews Tissue-Specific Methylation of Long Interspersed Nucleotide Element-1 of Homo Sapiens (L1Hs) During Human Embryogenesis and Roles in Neural Tube Defects
Current Molecular Medicine Synthesis, In Vitro Anticancer, Anti-Inflammatory and DNA Binding Activity of Thiazolidinedione Derivatives
Anti-Cancer Agents in Medicinal Chemistry Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Highly Selective MEK Inhibitors
Current Enzyme Inhibition Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Regulation of EMT by KLF4 in Gastrointestinal Cancer
Current Cancer Drug Targets Can Surgery for Inflammatory Bowel Disease be Personalized?
Current Drug Targets Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Current Protein & Peptide Science Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression
Current Pharmaceutical Design Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews